Results from a recent clinical trial to
treat lung cancer show that a novel immunotherapy combination is surprisingly effective at controlling the disease's progression.
In a groundbreaking development, results from a recent clinical trial to
treat lung cancer show that a novel immunotherapy combination is surprisingly effective at controlling the disease's progression.
«Molecule designed to
treat lung cancer shows promising results in mice.»
Not exact matches
In addition, the study
showed that the 5 - year survival rate for selected older patients with advanced
lung cancer who were
treated with surgical therapy was 29.9 % for Stage III and 26.7 % for Stage IV.
For example, the drug crizotinib approved to
treat ALK - positive
lung cancer,
showed a PFS of 10.9 months.
This
shows promise for breast
cancer patients as diagnosing and
treating the breast
cancer at early stages means there is a greater chance of preventing
cancer cells spreading to other tissues, such as the
lungs, brain and bone.
Previous work at CU
Cancer Center
shows these drugs are especially useful against
lung cancers that over-express both EGFR and HER2, implying that in addition to targeting HER2 - positive
lung cancers with drugs approved to
treat HER2 - positive breast
cancers, there may be a role for HER2 inhibitors in HER2
cancers, perhaps both breast and
lung.
Researchers and physicians have
shown success
treating EGFR
lung cancer, for example with EGFR inhibitors gefitinib and erlotinib.
November 14, 2006 Anti-
cancer drug
shows early promise in pulmonary hypertension A drug used to
treat kidney
cancer can prevent the development of pulmonary hypertension (high blood pressure in the
lungs) in rodents, report researchers from the University of Chicago at the 2006 annual meeting of the American Heart Association, November 12 to15, in Chicago.
DENVER — Elderly patients with stage III non-small cell
lung cancer (NSCLC)
showed improved overall survival (OS) when
treated with chemoradiation (CRT) compared to definitive radiation (RT) alone.
It has
shown great success in blood
cancers and is now being adopted to
treat mesothelioma and
lung cancer.
[4] Cell studies have
shown that vitamin C is toxic to prostate
cancer, [5] non-small cell
lung cancer, [6] and colon
cancer cells, [7] while animal studies have
shown that it may have some efficacy in the treatment of melanoma [8] and mesothelioma, the latter being notoriously difficult to
treat.